Leadership 2019-06-19T14:09:59+00:00

Professor Andrew Way
Chair, Governance Group, Monash Partners Comprehensive Cancer Consortium; Chief Executive, Alfred Health

Professor Way has served as Alfred Health’s Chief Executive since 2009. He is an Adjunct Clinical Professor at Monash University’s Faculty of Medicine, Nursing and Health Sciences, Director of  other health related organisations and is a member of several government and other advisory groups. Professor Way led the development of Victoria’s first Academic Health Science Centre – Monash Partners, which was accredited as an NHMRC Advanced Health and Research Translation Centre in 2015.  His focus is on improving access, ensuring high quality, safe services with low mortality, within a strong financial framework and a research-supportive environment.

Professor Melissa Southey
Research Director, Monash Partners Comprehensive Cancer Consortium (MPCCC); Chair of Precision Medicine, School of Clinical Sciences at Monash Health; Director, Biobanking Victoria, Monash University.

Professor Melissa Southey is a molecular geneticist (FHGSA), a Founding Fellow of the Faculty of Science, Royal College of Pathologists of Australasia (FFSc, RCPA), and is a National Health and Medical Research Council (NHMRC) Research Fellow. Professor Southey is best known for her work with multiple-case cancer families and heritable risk factors. Her research has provided the evidence base for best practice guidelines for clinical management of individuals at high risk of cancer. She leads multidisciplinary teams in diagnostic and research settings in Australia and internationally.

Professor Eva Segelov
Cancer and Blood Diseases Theme Clinical Director; Professor Director of Oncology, Monash Health and Monash University

Professor Eva Segelov is a recognised national and international expert in the fields of gastrointestinal cancer, neuroendocrine tumours, and breast cancer, with a 20 year history of management of patients in a multidisciplinary setting. Professor Segelov has led multiple national and international oncology clinical trials, including investigator-initiated studies. Her research interests relate to translational studies of targeted therapies in defined subpopulations to increase benefit and reduce the toxicity of cancer treatments.

Professor John Zalcberg OAM
Monash Partners Cancer and Blood Diseases Theme Representative; Head, Cancer Research Program, School of Public Health and Preventive Medicine, Monash University; Tony Charlton Chair of Oncology, The Alfred

Professor Zalcberg’s clinical research interests include gastrointestinal cancer and health care outcomes.  He leads projects in Clinical Quality Registries that collect patient outcome data for lung, ovarian and Upper GI cancers. He has an active involvement in clinical trials in GI cancers and continues an active clinical practice in GI cancer. Professor John Zalcberg was the Director, Division of Cancer Medicine, at the Peter MacCallum Cancer Centre in Melbourne, Australia for 17 years prior to recently taking up the position.

Associate Professor Zee Wan Wong
Joint Clinical Director, SMICS; Head of Oncology, Peninsula Health; Adjunct Clinical Associate Professor, Monash University; Senior Lecturer, University of Melbourne Medical School, Department of Rural Health

Dr Wong’s clinical focus includes breast and gastrointestinal cancers as well as immunotherapy.  Dr Wong has an active interest in clinical research and teaching, and is working towards expanding the oncology service, clinical trials and survivorship initiatives at Peninsula Health. In her role as joint SMICS Clinical Director, Dr Wong aims to contribute to the implementation and evaluation of the Optimal Care Pathways.

Dr Andrew Haydon
Joint Clinical Director, SMICS; Medical Oncologist, Alfred Health

Dr Haydon’s clinical interests are in the treatment of melanoma, head and neck cancer, and gastro-intestinal malignancies. He has been the Principal investigator in over 40 clinical trials and has authored or co-authored over 50 peer reviewed publications.  As SMICS joint Clinical Director  Dr Haydon will adopt a leading role in the improvement of oncology service delivery and referral pathways.